DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20204917

Hypereosinophilia presented as thromboembolic event: a rare manifestation

Sudhir K. Atri, Homdutt ., Manjri Goel, Devender Yadav

Abstract


Eosinophilia refers to peripheral blood absolute eosinophil count above the ULN, normal range of AEC is 0.05-0.5× 109/l (1-6%). Hyper eosinophilia refers to AEC above 1.5×109/l. Hypereosinophilia can affect multiple organs and can cause cardiomyopathy, gastroenteritis, cutaneous lesions, pneumonitis, and neuritis. In addition, some patients develop thromboembolic complications. We are presenting a case who presented to us with thromboembolic complication later diagnosed as hypereosinophilia with Bone marrow showing myeloid associated eosinophilia (Primary eosinophilia).


Keywords


Eosinophilia, Deep vein thrombosis, Pulmonary embolism, Thromboembolism

Full Text:

PDF

References


Lippi GI, Montagnana M, Salvagno GI, Franchini M, Targher G, Guidi GC, Eosinophilia and first-line coagulation testing, J. Thromb Haemost. 2013;11 (3):412–22.

Bain BJ. Chronic eosinophilic leukemia, not otherwise specified. World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues. 2008:51-3.

Sato Y, Fukunaga T, Hayashi T, Asada Y. Hypereosinophilic syndrome associated with occlusive coronary thrombosis and right ventricular thrombus. Pathol Int. 2008;58:138-41.

Uemura K, Nakajima M, Yamauchi N, Fukayama M, Yoshida K. Sudden death of a patient with primary hypereosinophilia, colon tumours, and pulmonary emboli. J Clin Pathol. 2004;57:541-3.

Sherer Y, Salomon O, Livneh A, Pras M, Langevitz P. Thromboembolism in a patient with transient eosinophilia and thrombocytopenia. Clin Lab Haematol. 2000;22:247-9.

Klion AD, Bochner BS, Gleich GJ, Nutman TB, Rothenberg ME, Simon HU, et al. Hypereosinophilic Syndromes Working Group. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Aller Clinic Immunol. 2006;117(6):1292-302.

Roufosse F, Weller PF. Practical approach to the patient with hypereosinophilia. J Aller Clinic Immunol. 2010;126(1):39-44.

Mukai HY, Ninomiya H, Ohtani K, Nagasawa T, Abe T. Major basic protein binding to thrombomodulin potentially contributes to the thrombosis in patients with eosinophilia. Brit J Haematol. 1995;90(4):892-9.

Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S, et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematol. 2007;92(9):1173-9.

Walz C, Erben P, Ritter M, Bloor A, Metzgeroth G, Telford N, et al. Response of ETV6-FLT3–positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. Blood, The Journal of the American Society of Hematology. 2011;118(8):2239-42.